Page 6 - Jared Silverman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Millions vanish into crypto world in high-yield bond scam Save Share Sophisticated British criminals exploited vulnerabilities in Australia’s search engine and cryptocurrency infrastructure to dupe small investors, lured by the promise of high-yield funds badged by some of the finance world’s most trusted brands. The complex scheme involved stolen identities and fraudulent prospectuses that claimed to represent high-yield investment funds run by global managers Citibank, Nomura, and IFM Investors. It has ensnared millions from unsuspecting victims who sought better returns as intere...

 E-Mail -AGREEMENT ADVANCES EVOLUTION OF SYNTHETIC LUNG SURFACTANTS TO TREAT RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS IN LOW- AND MIDDLE-INCOME COUNTRIES- LOS ANGELES (March 8, 2021) -- The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Can...

In-licensed candidate may be an effective intervention for premature infants with respiratory distress syndrome The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe. Newborns experiencing RDS must dramatically increase the effort to tak...

The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC).